DOI QR코드

DOI QR Code

Surgical Outcomes of Malignant Primary Cardiac Tumor: A 20-Year Study at a Single Center

  • Ryu, Seung Woo (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jeon, Bo Bae (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Ho Jin (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Joon Bum (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jung, Sung-Ho (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choo, Suk Jung (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chung, Cheol Hyun (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jae Won (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2020.05.21
  • 심사 : 2020.09.19
  • 발행 : 2020.12.05

초록

Background: Malignant primary cardiac tumors are extremely rare, but have a poor prognosis. This study evaluated the surgical outcomes of patients with this disease. Methods: Forty patients who underwent surgery for malignant primary cardiac tumors between January 1998 and December 2018 were enrolled. Participants were divided into 3 groups based on resection margins (R0, 14 patients; R1, 11 patients; and R2, 11 patients) and their surgical outcomes were compared. Heart transplantation was performed in 4 patients with unresectable tumors. Results: Early mortality was reported in 2 cases (5%) due to postoperative bleeding and cerebral hemorrhage secondary to brain metastasis. The 1- and 2-year survival rates were 67.5% and 42.5%, respectively. The median survival time of the patients was 20.3 months (range, 9.2-37.6 months). The median survival time was 48.7, 20.3, and 4.8 months in patients with R0, R1, and R2 resections, respectively (p=0.023). Tumor recurrence occurred in 21 patients (61.7%), including 4 cases of local recurrence and 17 cases of distant metastasis. In patients who underwent heart transplantation, the median survival time was 29.5 months, with 3 cases of distant metastasis. Conclusion: Although surgery for malignant primary cardiac tumors has a poor prognosis, complete resection of the tumor may improve surgical outcomes.

키워드

참고문헌

  1. Hamidi M, Moody JS, Weigel TL, Kozak KR. Primary cardiac sarcoma. Ann Thorac Surg 2010;90:176-81. https://doi.org/10.1016/j.athoracsur.2010.03.065
  2. Sellke FW, del Nido PJ, Swanson SJ. Sabiston and Spencer surgery of the chest. 9th ed. Philadelphia (PA): Elsevier; 2015.
  3. Putnam JB Jr, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DA. Primary cardiac sarcomas. Ann Thorac Surg 1991;51:906-10. https://doi.org/10.1016/0003-4975(91)91003-E
  4. Simpson L, Kumar SK, Okuno SH, et al. Malignant primary cardiac tumors: review of a single institution experience. Cancer 2008;112:2440-6. https://doi.org/10.1002/cncr.23459
  5. Ramlawi B, Leja MJ, Abu Saleh WK, et al. Surgical treatment of primary cardiac sarcomas: review of a single-institution experience. Ann Thorac Surg 2016;101:698-702. https://doi.org/10.1016/j.athoracsur.2015.07.087
  6. Li H, Yang S, Chen H, et al. Survival after heart transplantation for non-metastatic primary cardiac sarcoma. J Cardiothorac Surg 2016;11:145. https://doi.org/10.1186/s13019-016-0540-x
  7. Shanmugam G. Primary cardiac sarcoma. Eur J Cardiothorac Surg 2006;29:925-32. https://doi.org/10.1016/j.ejcts.2006.03.034
  8. Blackmon SH, Reardon MJ. Cardiac autotransplantation. Oper Tech Thorac Cardiovasc Surg 2010;15:147-61. https://doi.org/10.1053/j.optechstcvs.2010.03.002
  9. Cho WC, Kim HJ, Jung SH, Kim JJ, Kim DK. Heart transplantation with pulmonary vein reconstruction in Ewing's sarcoma in the right ventricular outflow tract. J Card Surg 2015;30:869-71. https://doi.org/10.1111/jocs.12610
  10. Cho WC, Jung SH, Lee SH, Bang JH, Kim J, Lee JW. Malignant peripheral nerve sheath tumor arising from the left ventricle. J Card Surg 2012;27:567-70. https://doi.org/10.1111/j.1540-8191.2012.01480.x
  11. Pacini D, Careddu L, Pantaleo A, et al. Primary malignant tumors of the heart: outcomes of the surgical treatment. Asian Cardiovasc Thorac Ann 2015;23:645-51. https://doi.org/10.1177/0218492315573674
  12. Bakaeen FG, Jaroszewski DE, Rice DC, et al. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg 2009;137:1454-60. https://doi.org/10.1016/j.jtcvs.2008.11.026
  13. Truong PT, Jones SO, Martens B, et al. Treatment and outcomes in adult patients with primary cardiac sarcoma: the British Columbia Cancer Agency experience. Ann Surg Oncol 2009;16:3358-65. https://doi.org/10.1245/s10434-009-0734-8
  14. Uberfuhr P, Meiser B, Fuchs A, et al. Heart transplantation: an approach to treating primary cardiac sarcoma? J Heart Lung Transplant 2002;21:1135-9. https://doi.org/10.1016/S1053-2498(02)00409-6
  15. Niu L, Luo X, Zeng J, et al. Cryoablation combined with Iodine-125 implantation in the treatment of cardiac metastasis from alveolar soft part sarcoma: a case report. Biomed Hub 2016;1:1-8.

피인용 문헌

  1. Cardiac angiosarcoma: A case report and review of the literature vol.38, pp.12, 2020, https://doi.org/10.1111/echo.15221